Market Cap
$288.8M
TMCI
TREACE MEDICAL CONCEPTS, INC.
$4.39 ▲ +1.39%
Prev close $4.33Market cap$288.8M
ConsensusStrong Sell
12-mo target$5.50 (+25.3%)
▼ Bearish
Analyst conviction 1/10
High Impact Filing (7/10)19 New Institutional Positions15 Institutional Exits Healthcare & Medical Devices
Snapshot
The big-picture read on TMCI right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Analyst Consensus
Sell (10%)
Inst. Holders
50 funds
Inst. Value
$72.9M
Inst. Activity
19 buys / 15 sells
Insider Activity
$1.5M buy / $0.00 sell
Insider Net $
$1.5M
SEC Reports
6
Price chart 30d -10.0%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 17, 2026 earnings
Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D® Study Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure
PONTE VEDRA, Fla., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the
Aug 24, 2026 Insider
Treace John T. bought 11,000 shares
Chief Executive Officer @ $4.34 ($47.7K)
Aug 21, 2026 Insider
Treace John T. bought 5,000 shares
Chief Executive Officer @ $4.35 ($21.7K)
Aug 20, 2026 Insider
Aug 7, 2026 SEC Treace John T. bought 39,944 shares
Chief Executive Officer @ $4.44 ($177.2K)
Treace Medical Concepts reported Q2 2026 revenue of $45.4M (down 4% YoY but beating $43.9M consensus) and EPS of -$0.24
8-K — Impact 6/10
The District of New Jersey granted Stryker's motion to dismiss Treace's antitrust (Sherman Act, Clayton Act, state antit
COURT-RULING — Impact 5/10
Jul 13, 2026 Event
TREACE MEDICAL CONCEPTS, INC. v. STRYKER CORPORATION et al
Court ruling (njd) — Docket: 2:24-cv-09763
Jun 30, 2026 Inst.
VANGUARD CAPITAL MANAGEMENT LLC — ADD
2,028,479 shares ($8.1M)
Analyst ratings buy % +11.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
10% rate it Buy or better · 10 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 10, 2026 | Truist Securities | MAINTAIN | Hold | 55% |
| Jul 16, 2026 | Truist Securities | MAINTAIN | Hold | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 0 | 1 | 5 | 2 | 2 | 10% | |
| Aug 1, 2026 | 0 | 1 | 5 | 2 | 2 | 10% | |
| Jul 1, 2026 | 0 | 1 | 5 | 2 | 2 | 10% | |
| Jun 1, 2026 | 0 | 1 | 5 | 2 | 2 | 10% | |
| May 1, 2026 | 0 | 1 | 5 | 2 | 2 | 10% | |
| Apr 1, 2026 | 0 | 1 | 5 | 2 | 2 | 10% | |
| Mar 1, 2026 | 0 | 1 | 6 | 2 | 2 | 9% | |
| Feb 1, 2026 | 0 | 1 | 6 | 2 | 2 | 9% |
Price targets
Where 3 covering analysts think TMCI trades over the next 12 months.
$5.50 +25.3% upside Strong Buy
Current$4.39 Low$4.50 Median$5.00 High$7.00 3 analysts
$4.50$7.00
Analyst rating Hold· 2.8/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
6 SEC filing reports analyzed · 0 bullish, 2 bearish, 2 mixed, 2 neutral · avg impact 4.8/10.
MIXED8-K6/10
Treace Medical Concepts reported Q2 2026 revenue of $45.4M (down 4% YoY but beating $43.9M consensus
Aug 7, 2026
BEARISHCOURT-RULING5/10
The District of New Jersey granted Stryker's motion to dismiss Treace's antitrust (Sherman Act, Clay
Jul 14, 2026
BEARISHPRESS-RELEASE7/10
Treace Medical Concepts reported Q1 2026 revenue of $47.2M (down 10% YoY) and a GAAP net loss of $(0
May 8, 2026
NEUTRALPRESS-RELEASE3/10
Treace Medical Concepts announced it will release Q1 2026 financial results on May 8, 2026, followed
Apr 24, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 17, 2026
earnings
Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D® Study Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure
PONTE VEDRA, Fla., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology
Sep 15, 2026
routine
Treace Highlights Product Innovations and Clinical Data Across its Expanding Foot & Ankle Portfolio at the 2026 AOFAS Annual Meeting
New product offerings extend bunion market leadership and accelerate penetration into new foot & ankle market adjacencies New product offerings extend
Aug 7, 2026
earnings
Treace Medical Concepts Reports Second Quarter 2026 Financial Results
PONTE VEDRA, Fla., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology
Aug 7, 2026
earnings_calendar
TMCI Q2 2026 Earnings After Market Close — 2026-08-07
Jul 13, 2026
Enforcement
TREACE MEDICAL CONCEPTS, INC. v. STRYKER CORPORATION et al
Court ruling (njd) — Docket: 2:24-cv-09763
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.25 | $-0.25–$-0.25 | -12.8% | -4.2% | 0↑ 1↓ | $0.0B | 1 |
| Next Q | $-0.11 | $-0.11–$-0.11 | -40.5% | -22.2% | 1↑ 0↓ | $0.1B | 1 |
| Current FY | $-0.85 | $-0.88–$-0.83 | 8.5% | +0.0% | 5↑ 0↓ | $0.2B | 5 |
| Next FY | $-0.85 | $-0.85–$-0.85 | — | +5.6% | 0↑ 1↓ | $0.2B | 1 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.250 | — |
| 7d ago | $-0.240 | -0.010 |
| 30d ago | $-0.240 | -0.010 |
| 60d ago | $-0.240 | -0.010 |
| 90d ago | $-0.230 | -0.020 |
Institutional ownership
Which big funds own TMCI (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $72.9M total value (18,315,786 shares) as of 2026-Q2. Top holders: BANK, VANGUARD, AQR. Net buying activity: 19 institutions added/increased vs 15 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | 3,305,100 | $13.2M | 18.0% | ADD +38.9% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,028,479 | $8.1M | 11.1% | ADD +38.8% |
| AQR CAPITAL MANAGEMENT LLC | 1,497,673 | $6.0M | 8.2% | — |
| BlackRock, Inc. | 1,380,021 | $5.5M | 7.5% | TRIM -58.7% |
| MARSHALL WACE, LLP | 1,328,592 | $5.3M | 7.3% | DOUBLED +401.5% |
| CIBC Bancorp USA Inc. | 1,216,044 | $4.8M | 6.6% | — |
| MILLENNIUM MANAGEMENT LLC | 738,628 | $2.9M | 4.0% | TRIM -35.7% |
| D. E. Shaw & Co., Inc. | 583,277 | $2.3M | 3.2% | TRIM -30.7% |
| GEODE CAPITAL MANAGEMENT, LLC | 573,796 | $2.3M | 3.1% | TRIM -43.2% |
| CITADEL ADVISORS LLC | 516,994 | $2.1M | 2.8% | TRIM -37.4% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | ADD | 1,461,507 | 2,028,479 | +38.8% | $8.1M |
| BlackRock, Inc. | TRIM | 3,340,023 | 1,380,021 | -58.7% | $5.5M |
| MARSHALL WACE, LLP | DOUBLED | 264,933 | 1,328,592 | +401.5% | $5.3M |
| MILLENNIUM MANAGEMENT LLC | TRIM | 1,148,115 | 738,628 | -35.7% | $2.9M |
| D. E. Shaw & Co., Inc. | TRIM | 841,269 | 583,277 | -30.7% | $2.3M |
| GEODE CAPITAL MANAGEMENT, LLC | TRIM | 1,010,843 | 573,796 | -43.2% | $2.3M |
| CITADEL ADVISORS LLC | TRIM | 825,575 | 516,994 | -37.4% | $2.1M |
| GOLDMAN SACHS GROUP INC | ADD | 387,685 | 492,116 | +26.9% | $2.0M |
| STIFEL FINANCIAL CORP | DOUBLED | 176,092 | 435,009 | +147.0% | $1.7M |
| UBS Group AG | TRIM | 542,905 | 366,445 | -32.5% | $1.5M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
10 insiders, 34 transactions. Net $1.5M — $1.5M bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 24, 2026 | Treace John T. | Chief Executive Officer | BUY | 11,000 | $4.34 | $47.7K |
| Aug 21, 2026 | Treace John T. | Chief Executive Officer | BUY | 5,000 | $4.35 | $21.7K |
| Aug 20, 2026 | Treace John T. | Chief Executive Officer | BUY | 39,944 | $4.44 | $177.2K |
| Aug 9, 2026 | Scanlan Sean F. | Chief Innovation Officer | TAX W/H | 9,814 | — | — |
| Aug 9, 2026 | Hair Mark | Chief Financial Officer | TAX W/H | 37,102 | — | — |
| Aug 9, 2026 | Elder Scot Michael | Chief Legl & Comp Off, CorpSec | TAX W/H | 16,253 | — | — |
| Jun 11, 2026 | Treace John T. | Chief Executive Officer | BUY | 22,887 | $4.04 | $92.5K |
| Jun 11, 2026 | Treace John T. | Chief Executive Officer | BUY | 9,891 | $4.04 | $40.0K |
| Jun 10, 2026 | Treace John T. | Chief Executive Officer | BUY | 29,430 | $4.02 | $118.4K |
| Jun 10, 2026 | Treace John T. | Chief Executive Officer | BUY | 14,715 | $4.02 | $59.2K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for TMCI.
Shares short
1,736,595
Settlement Sep 15, 2026
Change vs prior
+11.3%
Semi-monthly cycle
Days to cover
8.5
At avg daily volume
Of shares outstanding
≈2.7%
Estimate — not % of float
All TMCI filing & press-release reports (6)
- 8-K reportAug 7, 2026
- COURT-RULING reportJul 14, 2026
- PRESS-RELEASE reportMay 8, 2026
- PRESS-RELEASE reportApr 24, 2026
- 8-K reportApr 21, 2026
- DEFA14A reportApr 6, 2026